Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by itntdfon Feb 07, 2023 4:40pm
178 Views
Post# 35272930

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:PwC sees continuation of US$ 5 to 15 Billion Bio M&A Deals

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:PwC sees continuation of US$ 5 to 15 Billion Bio M&A Dealsdon't know what happened, but just lost my reply.

looked at lesaples' post and agree that mums been the word from oncy.  last substantive information from them (excepting the december 8 presentations) seems to have been the MDA dated march 22, 2022.

agree there is nothing on oncy's website which also seems strange.  however, given the exclusivity period which nobody can seem to definitively nail down, understandable that oncy would not be out blabbing about results or negotiations.

for those wondering why it's taking so long, it's DD.  while some may be annoyed by the back and forth over the AN agreement, it is just this kind of thing which is at the heart of DD.  can guarantee you big pharma was not going to be surprised that any disputes under the AN agreement would be resolved under the laws of hong kong.

also can guarantee you big pharma was not going to be surprised that the AN agreement was done under oncy's barbados company and with AN in china.

all of the confidential provisions of the AN agreement including various issues with supply development and distribution will be available to any big pharma with a serious interest in taking out oncy.  these agreements with AN are just some of what an interested suitor would examine in order to do a deep dive to understand what is what.

i find it curious that oncy's website characterizes the arrangement with AN under "partnering" when the actual agreement between AN and oncy say just the opposite:

The Parties desire to collaborate in conducting development and related activities, marketing in certain territories, and selling of product(s) containing Pelareorep for certain indications in those territories all on the terms and subject to the conditions set forth herein, but it is not the intention of the Parties to undertake an employment, joint venture, partnership or other fiduciary relationship.

27.1
The Parties are independent contractors and none of the provisions of this Agreement shall be deemed to constitute a partnership or joint venture between the Parties. 

 

like others here, a $2 billion buyout would make me an "oncy millionaire".  anything above that would be icing on the cake.

if notable's bolt-on projections are anywhere near correct, i will live out a very happy life in the event i don't have a heart attack seeing an over over $100 USD.


<< Previous
Bullboard Posts
Next >>